(Q41208022)

28 September 2017

title

Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations (English)

1 reference

28 September 2017

main subject

anti-retroviral agent

0 references

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25777740%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

Gary Maartens

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25777740%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

John A Joska

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25777740%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

author name string

Bernd Rosenkranz

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25777740%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

publication date

1 June 2015

1 reference

Clinical Pharmacokinetics

28 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25777740%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

volume

54

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25777740%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25777740%20AND%20SRC:MED&resulttype=core&format=json

6 June 2020

page(s)

581-598

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25777740%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s40262-015-0257-3

6 June 2020

exact match

0 references

cites work

HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Evolving clinical phenotypes in HIV-associated neurocognitive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Relationships among neurocognitive status, medication adherence measured by pharmacy refill records, and virologic suppression in HIV-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Antiretroviral neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Antiretroviral drugs and the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Clinical implications of CNS penetration of antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Steady-state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Protein-free efavirenz concentrations in cerebrospinal fluid and blood plasma are equivalent: applying the law of mass action to predict protein-free drug concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Protein binding in antiretroviral therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Regulation of ABC membrane transporters in glial cells: relevance to the pharmacotherapy of brain HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Drug interactions at the blood-brain barrier: fact or fantasy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Drug resistance in brain diseases and the role of drug efflux transporters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Genetic variation in drug transporters in ethnic populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Neuroimaging correlates of HIV-associated BBB compromise

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Antiretroviral medications disrupt microglial phagocytosis of β-amyloid and increase its production by neurons: implications for HIV-associated neurocognitive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid in HIV-1-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Compartmentalization and antiviral effect of efavirenz metabolites in blood plasma, seminal plasma, and cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

A systematic review of the psychiatric side-effects of efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Neuronal toxicity of efavirenz: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Stable concentrations of zidovudine, stavudine, lamivudine, abacavir, and nevirapine in serum and cerebrospinal fluid during 2 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Etravirine in CSF is highly protein bound

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Etravirine concentrations in CSF in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. The HIV Neurobehavioral Research Center Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Suppression of cerebrospinal fluid HIV burden in antiretroviral naive patients on a potent four-drug antiretroviral regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Low atazanavir concentrations in cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1--infected patients with and without AIDS dementia complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Lopinavir cerebrospinal fluid steady-state trough concentrations in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Raltegravir cerebrospinal fluid concentrations in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

MRP (ABCC) transporters-mediated efflux of anti-HIV drugs, saquinavir and zidovudine, from human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Active efflux across the blood-brain barrier: role of the solute carrier family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Genetic and non-genetic determinants of raltegravir penetration into cerebrospinal fluid: a single arm pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

A single-dose study to assess the penetration of stavudine into human cerebrospinal fluid in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

The role of compartment penetration in PI-Monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40262-015-0257-3

Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study

21 January 2018

1 reference

12 December 2020

Plasma and cerebrospinal fluid saquinavir concentrations in patients receiving combination antiretroviral therapy

1 reference

12 December 2020

Drug transporters in HIV Therapy

1 reference

12 December 2020

Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir

1 reference

12 December 2020

Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin

1 reference

12 December 2020

Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trial

1 reference

12 December 2020

Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children

1 reference

12 December 2020

The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies

1 reference

12 December 2020

Efficacy of nelfinavir-based treatment in the central nervous system of HIV-1 infected patients

1 reference

12 December 2020

Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma

1 reference

12 December 2020

The entry of antiviral and antiretroviral drugs into the central nervous system.

1 reference

12 December 2020

Overview of the pharmacogenetics of HIV therapy.

1 reference

12 December 2020

Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder

1 reference

12 December 2020

Penetration of 3'-amino-3'-deoxythymidine, a cytotoxic metabolite of zidovudine, into the cerebrospinal fluid of HIV-1-infected patients

1 reference

12 December 2020

Neurologic complications of HIV disease and their treatment

1 reference

12 December 2020

Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study

1 reference

12 December 2020